Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Axel Grothey

Hematology | Oncology
The West Clinic, PLLC
1588 Union Ave, 
Memphis, TN 
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
The West Clinic, PLLC
1588 Union Ave, 
Memphis, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Axel Grothey is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Grothey is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Colorectal Cancer, Febrile Neutropenia, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Hepatectomy.

His clinical research consists of co-authoring 256 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in TN
Hospital Affiliations
Regional One Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

THE WEST CLINIC, PLLC
1588 Union Ave, Memphis, TN 38104
Call: 901-300-1562
Other Locations
THE WEST CLINIC, PLLC
6005 Park Ave, Suite 700, Memphis, TN 38119
Call: 901-527-3391
THE WEST CLINIC, PLLC
7945 Wolf River Blvd, Germantown, TN 38138
Call: 901-683-0055
THE WEST CLINIC, PLLC
240 Grandview Dr, Brighton, TN 38011
Call: 901-475-0678
THE WEST CLINIC, PLLC
1290 Kelley Dr, Paris, TN 38242
Call: 901-683-0055

Additional Areas of Focus

Dr. Grothey has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
Enrollment Status: Completed
Publish Date: June 18, 2025
Intervention Type: Other, Drug
Study Drugs: Clobetasol propionate, Regorafenib
Study Phase: Phase 2
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 23, 2024
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Enrollment Status: Completed
Publish Date: July 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

256 Total Publications

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 05, 2025
View All 256 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Daniel Vaena
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Daniel Vaena
Hematology | Oncology

The West Clinic, PLLC

7668 Airways Blvd, 
Southaven, MS 
 (11.3 miles away)
662-349-9556
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Vaena is a Hematologist and an Oncologist in Southaven, Mississippi. Dr. Vaena is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, WT1-Related Wilms Tumor Syndromes, and Clear Cell Sarcoma.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kurt Tauer
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Kurt Tauer
Hematology | Oncology

The West Clinic, PLLC

1588 Union Ave, 
Memphis, TN 
 (0.1 miles away)
901-300-1562
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kurt Tauer is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Tauer is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Lung Cancer, and Familial Colorectal Cancer.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David Portnoy
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. David Portnoy
Hematology | Oncology

The West Clinic, PLLC

240 Grandview Dr, 
Brighton, TN 
 (27.5 miles away)
901-475-0678
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Portnoy is a Hematologist and an Oncologist in Brighton, Tennessee. Dr. Portnoy is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Liposarcoma, Adult Soft Tissue Sarcoma, Rhabdomyosarcoma Embryonal, Retroperitoneal Liposarcoma, and Pancreaticoduodenectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grothey's expertise for a condition
ConditionClose
  • Elite
  • Colorectal Cancer
    Dr. Grothey is
    Elite
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Distinguished
  • Agranulocytosis
    Dr. Grothey is
    Distinguished
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Familial Colorectal Cancer
    Dr. Grothey is
    Distinguished
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Febrile Neutropenia
    Dr. Grothey is
    Distinguished
    . Learn about Febrile Neutropenia.
    See more Febrile Neutropenia experts
  • Lynch Syndrome
    Dr. Grothey is
    Distinguished
    . Learn about Lynch Syndrome.
    See more Lynch Syndrome experts
  • Pancreatic Cancer
    Dr. Grothey is
    Distinguished
    . Learn about Pancreatic Cancer.
    See more Pancreatic Cancer experts
  • Advanced
  • Anal Cancer
    Dr. Grothey is
    Advanced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Appendix Cancer
    Dr. Grothey is
    Advanced
    . Learn about Appendix Cancer.
    See more Appendix Cancer experts
  • Breast Cancer
    Dr. Grothey is
    Advanced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Grothey is
    Advanced
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Esophageal Cancer
    Dr. Grothey is
    Advanced
    . Learn about Esophageal Cancer.
    See more Esophageal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Grothey is
    Advanced
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
View All 20 Advanced Conditions
  • Experienced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Grothey is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Grothey is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Grothey is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Acute Promyelocytic Leukemia
    Dr. Grothey is
    Experienced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Adrenal Cancer
    Dr. Grothey is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adrenocortical Carcinoma
    Dr. Grothey is
    Experienced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
View All 100 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved